Why Athersys Stock Jumped Today
The biotech announced the enrollment of the first patient in a key clinical study.
Athersys
ATHX
ATHX
$2.15
$0.21
10.8%
Price as of January 25, 2021, 9:00 p.m. EST
View Interactive ATHX Charts
Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.
Interactive Chart
News & Analysis: Athersys
Athersys (ATHX) Q3 2020 Earnings Call Transcript
ATHX earnings call for the period ending September 30, 2020.
Athersys (ATHX) Q2 2020 Earnings Call Transcript
ATHX earnings call for the period ending June 30, 2020.
Here's Why Athersys Stock Is Soaring Today
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
Here's Why Athersys Rose 26.5% in May
The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.
Athersys (ATHX) Q1 2020 Earnings Call Transcript
ATHX earnings call for the period ending March 31, 2020.
Here's Why Athersys Tumbled 23.3% in April
The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?
Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
Athersys Stock Tumbles as Much as 27.7% on a Public Offering
The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.
Athersys (ATHX) Q3 2019 Earnings Call Transcript
ATHX earnings call for the period ending September 30, 2019.
